MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780

Nils Brünner, Thomas L. Frandsen, Claus Holst-Hansen, Mian Bei, Erik W. Thompson, Alan E. Wakeling, Marc E Lippman, Robert Clarke

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

The development of resistance to the antiestrogen tamoxifen occurs in a high percentage of initially responsive patients. We have developed a new model in which to investigate acquired resistance to triphenylethylenes. A stepwise in vitro selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LCC2. MCF7/LCC2 cells retain levels of estrogen receptor expression comparable to the parental MCF7/LCC1 and MCF-7 cells. Progesterone receptor expression remains estrogen inducible in MCF7/LCC2 cells, although to levels significantly lower than observed in MCF-7 and MCF7/LCC1 cells. MCF7/ LCC2 cells form tumors in ovariectomized nude mice without estrogen supplementation, and these tumors are tamoxifen resistant but can be tstrogen stimulated. Significantly, MCF7/LCC2 cells have retained sensitivity to the steroidal antiestrogen ICI 182,780. These data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.

Original languageEnglish
Pages (from-to)3229-3232
Number of pages4
JournalCancer Research
Volume53
Issue number14
StatePublished - Jul 15 1993
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
MCF-7 Cells
Breast Neoplasms
Tamoxifen
Estrogens
Population Dynamics
Progesterone Receptors
Nude Mice
Estrogen Receptors
fulvestrant
afimoxifene
Neoplasms
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brünner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., ... Clarke, R. (1993). MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Research, 53(14), 3229-3232.

MCF7/LCC2 : A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. / Brünner, Nils; Frandsen, Thomas L.; Holst-Hansen, Claus; Bei, Mian; Thompson, Erik W.; Wakeling, Alan E.; Lippman, Marc E; Clarke, Robert.

In: Cancer Research, Vol. 53, No. 14, 15.07.1993, p. 3229-3232.

Research output: Contribution to journalArticle

Brünner, N, Frandsen, TL, Holst-Hansen, C, Bei, M, Thompson, EW, Wakeling, AE, Lippman, ME & Clarke, R 1993, 'MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780', Cancer Research, vol. 53, no. 14, pp. 3229-3232.
Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE et al. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Research. 1993 Jul 15;53(14):3229-3232.
Brünner, Nils ; Frandsen, Thomas L. ; Holst-Hansen, Claus ; Bei, Mian ; Thompson, Erik W. ; Wakeling, Alan E. ; Lippman, Marc E ; Clarke, Robert. / MCF7/LCC2 : A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. In: Cancer Research. 1993 ; Vol. 53, No. 14. pp. 3229-3232.
@article{e946e3a03d85496ca94bd73a7ff282ab,
title = "MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780",
abstract = "The development of resistance to the antiestrogen tamoxifen occurs in a high percentage of initially responsive patients. We have developed a new model in which to investigate acquired resistance to triphenylethylenes. A stepwise in vitro selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LCC2. MCF7/LCC2 cells retain levels of estrogen receptor expression comparable to the parental MCF7/LCC1 and MCF-7 cells. Progesterone receptor expression remains estrogen inducible in MCF7/LCC2 cells, although to levels significantly lower than observed in MCF-7 and MCF7/LCC1 cells. MCF7/ LCC2 cells form tumors in ovariectomized nude mice without estrogen supplementation, and these tumors are tamoxifen resistant but can be tstrogen stimulated. Significantly, MCF7/LCC2 cells have retained sensitivity to the steroidal antiestrogen ICI 182,780. These data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.",
author = "Nils Br{\"u}nner and Frandsen, {Thomas L.} and Claus Holst-Hansen and Mian Bei and Thompson, {Erik W.} and Wakeling, {Alan E.} and Lippman, {Marc E} and Robert Clarke",
year = "1993",
month = "7",
day = "15",
language = "English",
volume = "53",
pages = "3229--3232",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - MCF7/LCC2

T2 - A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780

AU - Brünner, Nils

AU - Frandsen, Thomas L.

AU - Holst-Hansen, Claus

AU - Bei, Mian

AU - Thompson, Erik W.

AU - Wakeling, Alan E.

AU - Lippman, Marc E

AU - Clarke, Robert

PY - 1993/7/15

Y1 - 1993/7/15

N2 - The development of resistance to the antiestrogen tamoxifen occurs in a high percentage of initially responsive patients. We have developed a new model in which to investigate acquired resistance to triphenylethylenes. A stepwise in vitro selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LCC2. MCF7/LCC2 cells retain levels of estrogen receptor expression comparable to the parental MCF7/LCC1 and MCF-7 cells. Progesterone receptor expression remains estrogen inducible in MCF7/LCC2 cells, although to levels significantly lower than observed in MCF-7 and MCF7/LCC1 cells. MCF7/ LCC2 cells form tumors in ovariectomized nude mice without estrogen supplementation, and these tumors are tamoxifen resistant but can be tstrogen stimulated. Significantly, MCF7/LCC2 cells have retained sensitivity to the steroidal antiestrogen ICI 182,780. These data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.

AB - The development of resistance to the antiestrogen tamoxifen occurs in a high percentage of initially responsive patients. We have developed a new model in which to investigate acquired resistance to triphenylethylenes. A stepwise in vitro selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LCC2. MCF7/LCC2 cells retain levels of estrogen receptor expression comparable to the parental MCF7/LCC1 and MCF-7 cells. Progesterone receptor expression remains estrogen inducible in MCF7/LCC2 cells, although to levels significantly lower than observed in MCF-7 and MCF7/LCC1 cells. MCF7/ LCC2 cells form tumors in ovariectomized nude mice without estrogen supplementation, and these tumors are tamoxifen resistant but can be tstrogen stimulated. Significantly, MCF7/LCC2 cells have retained sensitivity to the steroidal antiestrogen ICI 182,780. These data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.

UR - http://www.scopus.com/inward/record.url?scp=0027279120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027279120&partnerID=8YFLogxK

M3 - Article

C2 - 8324732

AN - SCOPUS:0027279120

VL - 53

SP - 3229

EP - 3232

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -